Phase 2 ALD Clinical Trials

24 recruitingPhase 2

What is a Phase 2 trial?

Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.

Showing 120 of 24 trials

Recruiting
Phase 2

A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism

Primary Aldosteronism
Shandong Suncadia Medicine Co., Ltd.60 enrolled2 locationsNCT07470983
Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled127 locationsNCT05006716
Recruiting
Phase 1Phase 2

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 2

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 2

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
National Cancer Institute (NCI)92 enrolled125 locationsNCT04840602
Recruiting
Phase 2

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
AbbVie14 enrolled7 locationsNCT07387471
Recruiting
Phase 2Phase 3

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

ObesityCardiovascular DiseasesHypertension+3 more
University of Alabama at Birmingham160 enrolled1 locationNCT04971720
Recruiting
Phase 2

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

Waldenstrom Macroglobulinemia
Massachusetts General Hospital55 enrolled5 locationsNCT06561347
Recruiting
Phase 2

Epcoritamab in Previously Treated WM

Waldenstrom MacroglobulinemiaB-Cell Lymphoproliferative Disorder
Gottfried von Keudell, MD PhD20 enrolled3 locationsNCT06510491
Recruiting
Phase 1Phase 2

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoplasmacytic Lymphoma+4 more
ModeX Therapeutics, An OPKO Health Company180 enrolled1 locationNCT07249905
Not Yet Recruiting
Phase 2

ALLG NHL43: An open-label multi-centre international phase 2 trial to evaluate the safety and efficacy of two years fixed duration therapy with sonrotoclax in combination with the BGB-16673 and rituximab in patients with treatment naïve or BTKi naïve/intolerant Waldenström Macroglobulinemia (WM).

Waldenström Macroglobulinemia (WM)
Australasian Leukaemia and Lymphoma Group80 enrolled2 locationsACTRN12626000174381
Recruiting
Phase 2

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

HypercortisolismHyperaldosteronismCushing s Syndrome
National Cancer Institute (NCI)80 enrolled1 locationNCT06246357
Recruiting
Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

Lymphoplasmacytic LymphomaWaldenström MacroglobulinemiaB-Cell Lymphoproliferative Disorder+1 more
Shayna Sarosiek, MD30 enrolled1 locationNCT06986174
Recruiting
Phase 2

Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia

Waldenstrom MacroglobulinemiaTreatment Naive
Christian Buske80 enrolled11 locationsNCT05099471
Recruiting
Phase 2

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
Memorial Sloan Kettering Cancer Center40 enrolled8 locationsNCT07231952
Recruiting
Phase 1Phase 2

Autologous Adipose Cells Therapy

Hair ThinningHair Loss/BaldnessWrinkle Appearance+5 more
CERM INC.40 enrolled2 locationsNCT06869252
Recruiting
Phase 2

Loncastuximab Tesirine in WM

Waldenstrom Macroglobulinemia
Shayna Sarosiek, MD36 enrolled4 locationsNCT05190705
Recruiting
Phase 2

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia
Dana-Farber Cancer Institute42 enrolled2 locationsNCT05734495
Recruiting
Phase 1Phase 2

Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism

Primary AldosteronismPrimary Aldosteronism Due to Aldosterone Producing Adenoma
Peking Union Medical College Hospital150 enrolled1 locationNCT06773663
Recruiting
Phase 1Phase 2

Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate

Primary Aldosteronism
University Medical Center Groningen12 enrolled1 locationNCT06616142